- Details
- Description
-
Packaging Size28c/Bottle
-
Strength12.5mg&25mg&50mg
-
CompositonSunitinib
-
TreatmentGastrointestinal stromal tumors（GIST）,Renal cell carcinoma（RCC），Pancreatic Neuroendocrine Tumor（PNETs）
-
FormCapsule
-
BrandLuciSuni
-
Quantity Unit12.5mg*28c/Box&25mg*28c/Box&50mg*28c/Box
-
ManufacturerLucius Pharmaceuticals (Lao) Co.,Ltd
About Sunitinib
Sunitinib is an anti-cancer medication. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) in January 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.
Gastrointestinal Stromal Tumor
Indicated for treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate
50 mg PO qDay for 4 weeks, THEN 2 weeks drug-free, repeat cycle
Continue until disease progression or unacceptable toxicity
Renal Cell Carcinoma
Indicated for treatment of advanced renal cell carcinoma (RCC)
50 mg PO qDay for 4 weeks, THEN 2 weeks drug-free, repeat cycle
Continue until disease progression or unacceptable toxicity
Adjuvant treatment of RCC
- Indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy
- 50 mg PO qDay for 4 weeks, THEN 2 weeks drug-free, repeat cycle for a total of nine 6-week cycles
Pancreatic Neuroendocrine Tumors
Indicated for progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease
37.5 mg PO qDay continuously without a scheduled off-treatment period
Continue until disease progression or unacceptable toxicity
